User login
Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.
Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531; 95% CI 4.156-21.861) and MDS (HR 2.559; 95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.
Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952
Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.
Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531; 95% CI 4.156-21.861) and MDS (HR 2.559; 95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.
Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952
Key clinical point:Although the cumulative incidence of myeloid neoplasms, such as myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML), was low in breast cancer (BC) survivors, the receipt of anthracycline-based adjuvant therapy was associated with a long-term risk for both AML and MDS.
Major finding: The 10-year cumulative incidences of both AML and MDS were very low (~0.2%) in the anthracycline group and <0.2% in the chemotherapy without anthracycline and no chemotherapy groups. However, the risk for AML (hazard ratio [HR] 9.531; 95% CI 4.156-21.861) and MDS (HR 2.559; 95% CI 1.600-4.095) was significantly higher in the anthracycline group vs no chemotherapy group.
Study details: Findings are from a retrospective cohort study including 153,565 patients with BC who underwent surgery and received adjuvant treatment with anthracyclines (n = 79,321), chemotherapy without anthracyclines (n = 15,475), or no chemotherapy (n = 46,657).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Lee JW et al. Therapy related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy. Eur J Cancer. 2023;191:112952 (Jun 22). Doi: 10.1016/j.ejca.2023.112952